Navigating Recent Scientific Advances in Atopic Dermatitis: Skin BarrierDysfunction, Dysbiosis, and Itch
Dermatology
Experts discuss the latest evidence on how type 2 inflammation drives skin barrierdysfunction, affects the skin microbiome, and contributes to neuroimmune dysregulation in AD.
Role of Type 2 Inflammation in Skin BarrierDysfunction in AD
Type 2 Inflammation
Dr. Robert Bissonnette explains the role of type 2 inflammation in skin barrierdysfunction and how regulation of type 2 inflammation can normalize the skin barrier and potentially modify the disease with early intervention.
The Association Between Epidermal BarrierDysfunction and S. aureus Colonization in Atopic Dermatitis
Dermatology
Dr. Lisa Beck highlights the association between epidermal barrierdysfunction and S. aureus colonization in her talk at the ISDS 2023 ADVENT symposium.
In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrierdysfunction and AD signs and symptoms.
Skin BarrierDysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)
Dermatology
An infographic exploring the process of allergen sensitization and the impact it may have on the development of atopic comorbidities in children with AD.
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Dermatology
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrierdysfunction, and neuroimmune dysregulation
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
